Remote capillary blood collection for HbA$_{1c}$ measurement during the COVID-19 pandemic: A laboratory and patient perspective

Wendy N. Groenendijk$^1$ | Tomás P. Griffin$^{2,3}$ | Md N. Islam$^1$ | Liam Blake$^1$
| Deirdre Wall$^4$ | Marcia Bell$^2$ | Paula M. O’Shea$^{1,3}$

$^1$Department of Clinical Biochemistry, Saolta University Health Care Group (SUHCG), Galway University Hospitals, Galway, Ireland
$^2$Centre for Endocrinology, Diabetes Mellitus and Metabolism, Saolta University Health Care Group (SUHCG), Galway University Hospitals, Galway, Ireland
$^3$School of Medicine, National University of Ireland Galway (NUIG), Galway, Ireland
$^4$School of Mathematics, Statistics and Applied Mathematics, National University of Ireland Galway (NUIG), Galway, Ireland

Correspondence
Paula M. O’Shea, Department of Clinical Biochemistry, Saolta University Health Care Group (SUHCG), Galway University Hospitals, Newcastle Road, Galway, Ireland.
Email: paulaoshea28@gmail.com

Abstract

**Aims:** The purpose of this study was to assess the clinical performance and user acceptance of capillary blood samples prepared remotely using the MiniCollect® capillary blood collection device as an alternative to blood collection by venepuncture for glycated haemoglobin (HbA$_{1c}$) analysis.

**Methods:** Following written informed consent, a cross-sectional study was conducted in individuals aged ≥ 18 years with any type of diabetes who routinely self-monitor their blood glucose. Eligible participants recruited whilst attending their routine clinical appointments were required to provide a venous blood sample, prepare a capillary blood sample at home (remotely) and complete a bespoke questionnaire. HbA$_{1c}$ in whole blood collected in ethylenediaminetetraacetic acid was determined by capillary electrophoresis on the Sebia Capillary’s 3 Tera analyser following standard operating procedure.

**Results:** HbA$_{1c}$ results from both venous and capillary collection demonstrated good agreement. Passing-Bablok regression: $y = 0 + 1x$ ($p = 0.18$), Spearman correlation $r = 0.986$, $p < 0.0001$. The Bland–Altman difference plot provided a mean difference of 0.3 mmol/mol (2.2%). Over half of the participants found the MiniCollect device easy to use. The majority of participants were in favour of the remote capillary blood collection service and would use it if routinely available.

**Conclusion:** The home collection of capillary blood for HbA$_{1c}$ determination is a valuable and convenient alternative to standard venous blood collection as it provides an opportunity to support routine HbA$_{1c}$ monitoring, whilst mitigating the transmission of SARS-CoV-2. This service would additionally allow individuals to attend clinic visits with a HbA$_{1c}$ value, ensuring optimal continuance of patient care for individuals with diabetes.

**KEYWORDS**
capillary sampling, delivery of care, glycaemic control, HbA$_{1c}$, remote monitoring

Prior presentation: An abstract of this study was accepted for the 45th Irish Endocrine Society Annual Meeting hosted virtually on the 19/20 November 2021.
1 | INTRODUCTION

Diabetes is a chronic disease in which individuals require ongoing support from diabetes services. The severity of the current COVID-19 pandemic has disrupted this provision of support; to minimize the spread of SARS-CoV-2 infection and to support social distancing measures, many phlebotomy appointments have been stopped and face-to-face consultations replaced by remote virtual or telephone appointments. Consequently, people with diabetes have had reduced access to routine appointments and regular monitoring of glycated haemoglobin (HbA1c). HbA1c is the product of in vivo non-enzymatic glycation of haemoglobin, a process which is proportional to the plasma glucose concentration and occurs throughout the lifespan of a red blood cell (RBC). The average lifespan of an RBC is 120 days. HbA1c is a time-weighted average of blood glucose concentrations, meaning that of the 120-day RBC lifespan, the average plasma glucose for the 30 days preceding blood sampling contributes to 50% of the HbA1c value, whilst glucose levels from the previous 90–120 days contribute only 10%.

HbA1c is currently the gold standard test for monitoring glycaemic control in individuals with diabetes and predicts the risk of developing chronic microvascular complications. The Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS) demonstrated a clear correlation between glycaemic control and microvascular complications and the results of these trials subsequently led to the recommendations for glycaemic targets based on HbA1c concentrations.

The COVID-19 pandemic has resulted in a significant reduction in HbA1c testing. This has led to difficulties in monitoring glycaemic control and identifying people whose glycaemic control is not to target. Delayed detection of diabetes and prolonged suboptimal control increase the risk of individuals developing serious long-term complications of diabetes, which, in turn, place an economic burden on health services and significantly reduce the quality of life of people with diabetes.

An alternative way to increase accessibility to HbA1c laboratory testing is required in order to support routine HbA1c testing whilst mitigating the risk of SARS-CoV-2 infection and transmission. The self-collection of capillary blood samples provides a feasible alternative approach that can support remote provision of care for individuals with diabetes.

The primary aim of this study was to determine whether HbA1c analysis of blood obtained by fingerprick, collected remotely, agrees with HbA1c analysis of blood collected by the standard method of venous blood collection. The secondary aim was to assess the user acceptance of the remote HbA1c service as a potential alternative to venous blood collection.

What’s new

- The COVID-19 pandemic has challenged the traditional way health services are delivered. Consequently, there has been a significant reduction in face-to-face consultations and routine phlebotomy. For people with diabetes, the inability to have blood collected for glycated haemoglobin (HbA1c) measurement has resulted in suboptimal assessment of glycaemic control.
- This study demonstrates that HbA1c levels measured from remotely prepared capillary samples are clinically concordant with HbA1c measured from blood collected by venepuncture.
- Remote capillary blood collection can enable people with diabetes to take control of their own HbA1c blood sampling and provide an opportunity to support HbA1c monitoring during the COVID-19 pandemic.

2 | METHODS

2.1 | Study design

A cross-sectional study of individuals with diabetes was conducted between June and July 2021. Eligible participants were recruited whilst attending their routine clinical appointments at the Galway University Hospital and Roscommon University Hospital. The purpose of the study was outlined to eligible participants using a specifically designed patient information leaflet. During their routine appointment, each participant had a venous sample collected for routine measurement of HbA1c. Following informed written consent, participants were asked to provide an additional blood sample (capillary) which was to be collected remotely. They were provided with a home-pack for the collection and return of the home-prepared capillary sample. The home-pack included a stamped addressed envelope, a labelled MiniCollect® capillary blood collection device, a leakproof container, an instruction leaflet, a five-level questionnaire and a labelled laboratory request form. The postal HbA1c service instruction leaflet which included a link to a pre-existing YouTube video was created to aid participants in capillary sample collection.
2.2 | Reference population

The inclusion criteria were written informed consent, individuals aged ≥18 years with any type of diabetes who routinely self-monitor their blood glucose. Individuals without diabetes, age <18 years, pregnant women and persons receiving renal replacement therapy were excluded.

2.3 | Sample collection

2.3.1 | Venous blood collection

During their routine clinic appointment, each participant had a venous whole blood sample collected into a potassium ethylenediaminetetraacetic acid (EDTA) collection tube (Greiner Bio-One Vacuette® 3 ml K3E K3EDTA) for routine measurement of HbA1c.

2.3.2 | Capillary blood collection

Each participant was asked to provide a capillary blood sample which was to be collected into the Greiner Bio-One 0.25/0.5 ml K3E K3EDTA MiniCollect device (Figure 1) at home.

Participants were shown by the clinical team how to use the MiniCollect device and a home-pack was provided to each participant. Participants were asked to collect 250μl of capillary blood into the MiniCollect device within 24h of venous blood collection and to post the capillary sample within 24h of its preparation to the laboratory for HbA1c analysis.

2.4 | Laboratory HbA1c analysis

HbA1c in venous and capillary whole blood collected into EDTA was determined by capillary electrophoresis on the Sebia Capillary's 3 Tera automated platform using the Sebia HbA1c kit. This assay is accredited to ISO:15189:2012 standards.

The 0.25/0.5 ml gradation markings on MiniCollect tube facilitated an approximate visual assessment of the capillary blood volume for each sample. For low-volume whole blood samples, in accordance with the instruction for use, prior to analysis 20μl of capillary/venous blood was transferred into a low-volume collection tube containing 100μl haemolysing solution.

2.6 | Statistical analysis

Statistical analyses were performed using Analyze-it® (Version 17) and MedCalc® Statistical Software (Version 20.027). Tests for normality were performed on all variables using the Shapiro–Wilk normality test. Gaussian data were represented as the mean (±standard deviation) and non-Gaussian data as the median (range). Descriptive statistics were performed on the baseline characteristics. A histogram and box and whisker plot were used to illustrate the distribution of the data. The statistical

FIGURE 1  A MiniCollect capillary blood collection with and without capillary blood (Adapted from Ref. [10]).
differences in the median HbA1c values from the two collection methods were analysed using the Mann–Whitney U test. A p-value of <0.05 was deemed statistically significant. The relationship between the venous and capillary whole blood sample for HbA1c was assessed using the Spearman’s rank coefficient. Passing-Bablok regression analysis and the Bland-Altman difference plot were used to assess the agreement and bias between the results for HbA1c using the two collection methods in accordance with the Clinical Laboratory and Standards Institute (CLSI) guidance EP09-A3.12

The questionnaire was used to assess participant’s experience with the MiniCollect device and acceptance of the postal HbA1c service.

3 | RESULTS

3.1 | Participant characteristics

A total of 84 participants were recruited to this study. The reference population comprised of more men (n = 49) than women (n = 35); the median age was 44 (19–85) years.

3.2 | Returned capillary samples

Of the 84 participants recruited to this study, 22 did not complete the study and return their capillary sample to the laboratory. Possible reasons for this include: the sample was not received in the laboratory, the participant was unable to collect the capillary sample or the participant no longer wished to participate.

Of the 62 capillary samples received in the laboratory, 16 did not have a concomitant venous sample (collected within 24h) and 5 were of insufficient volume (<20μl) to permit HbA1c analysis. In total, there were 41 capillary samples that met the study inclusion criteria with a paired venous sample collected within 24h of the capillary sample collection (Figure 2).

Furthermore, it was determined that six participants, who had prepared a capillary sample for HbA1c analysis remotely but omitted to undergo venepuncture for HbA1c, had a venous sample collected and analysed for HbA1c in the month prior to their capillary sample collection.

The average volume of capillary blood collected by the 62 participants was 175μl. Sample volume appeared to vary with age: individuals aged >50 years (n = 27) had an approximate blood volume of 146μl whilst participants >70 years (n = 7) collected the smallest amount of blood with an average volume of 75μl. Regression analysis revealed no correlation between the age of the participant and the volume of capillary blood collected (R = 0.12, p = 0.0053).

3.3 | Study population

Baseline characteristics of the 41 participants who met the inclusion criteria are shown in Table 1.

3.4 | HbA1c analysis

The HbA1c results determined in venous blood were designated the reference comparator result for this study. The HbA1c results from venous and capillary samples were almost identical (p = 0.849). A wide range of HbA1c concentrations were used to compare HbA1c results collected by venepuncture and fingerprick (capillary whole blood): the minimum HbA1c concentration

![Figure 2](image-url)
for both capillary and venous samples was 41 mmol/mol (5.9%) and the maximum concentrations for venous and capillary samples were 131 and 129 mmol/mol (14.1% and 14%), respectively. The median HbA1c results were 62 mmol/mol (7.8%) and 63 mmol/mol (7.9%) for the venous and capillary samples, respectively. HbA1c results from capillary samples exhibited a strong positive correlation with the routine venous HbA1c collection method (\( r = 0.986, p < 0.0001 \)).

The Passing-Bablok regression line of \( y = 0 + 1x \) revealed a slope of 1 (95% confidence interval [CI]: 0.9697–1.0400) and an intercept of 0 (95% CI: −2.2000 to 1.8485). The Cusum test for linearity revealed no significant deviation from linearity (\( p = 0.18 \)). The Bland-Altman difference plot (Figure 3) showed a mean difference of 0.3 mmol/mol (2.2%) (95% CI: −0.44 to 1.07) between the two collection methods. The limits of agreement ranged from 4.4 mmol/mol (2.6%) (95% CI: −5.67 to −0.07) to 5 mmol/mol (2.6%) (95% CI: 3.70–6.31). The majority of HbA1c values (95%) fell within the limits of agreement. All HbA1c results except one fell within the maximum acceptable difference of 5 mmol/mol (2.6%), a difference which was selected a priori. This value, 5 mmol/mol (2.6%), was chosen as the maximum allowable difference as it is based on the smallest difference in HbA1c concentrations in consecutive HbA1c tests that guide physicians to change therapy.13,14

All HbA1c results for the six participants who had a venous sample collected a month prior to capillary sample collection were within 5 mmol/mol (2.6%) of that obtained from the home-prepared capillary sample.

### 3.5 | Questionnaire

Of the 62 participants who returned capillary samples, 60 returned with a questionnaire of which 57 were completed.

The first section of the questionnaire was used to assess participants’ experience with the MiniCollect device (Table 2). The majority (92.3% [48/52]) of the respondents found the written instructions-for-use very easy (73.1% [38/52]) or easy to use (19.2% [10/52]). Of those respondents who followed the instructions-for-use video on YouTube (\( n = 30 \)), the majority found the video very easy (60.0% [18/30]) or easy to use (26.7% [8/30]). In total, 57.1% (32/56) of respondents found the MiniCollect device very easy or easy to use, whilst 25.0% (14/56) found the device difficult or very difficult to use. Participants appeared to have the most difficulty obtaining enough blood

### TABLE 1

| Type of diabetes | Men (n) | Women (n) | Age (years) Median (range) | Duration of diabetes (years) Median (range) |
|------------------|--------|----------|---------------------------|---------------------------------|
| T1DM             | 15     | 9        | 37.5 (19–69)              | 17 (0–37)                       |
| T2DM             | 9      | 6        | 36 (36–81)                | 8 (0–39)                        |
| Other            | 0      | 2        | 67.5 (67–68)              | 24.5 (1–48)                     |
| Total (n = 41)   | 24     | 17       | 47 (19–81)                | 13 (0–48)                       |

Note: Other: 1× MODY (maturity-onset diabetes of the young) type 3 and 1× secondary diabetes mellitus.
TABLE 2 Analysis of questionnaire responses used to assess participants’ experience with the MiniCollect collection device and the overall postal glycated haemoglobin (HbA1c) service

| I found... | Number of responses to each question (n) | Very easy to use % (n) | Easy % (n) | Neither easy nor difficult % (n) | Difficult % (n) | Very difficult % (n) |
|-----------|------------------------------------------|------------------------|----------|-------------------------------|----------------|---------------------|
| Following the written instructions-for-use | 52 | 73.1 (38) | 19.2 (10) | 3.8 (2) | 3.8 (2) | 0.0 (0) |
| Following the instruction-for-use video on YouTube | 30 | 60.0 (18) | 26.7 (8) | 6.7 (2) | 6.7 (2) | 0.0 (0) |
| The MiniCollect capillary blood collection device easy to use | 56 | 33.9 (19) | 23.2 (13) | 17.9 (10) | 19.6 (11) | 5.4 (3) |
| Getting enough blood was | 57 | 8.8 (5) | 12.3 (7) | 15.8 (9) | 38.6 (22) | 24.6 (14) |
| Deciding when I had enough blood | 57 | 21.1 (12) | 31.6 (18) | 19.3 (11) | 17.5 (10) | 10.5 (6) |
| Securing the cap on the collection device | 56 | 66.1 (37) | 25.0 (14) | 7.1 (4) | 0.0 (0) | 1.8 (1) |
| Posting sample on the day of preparation | 52 | 51.9 (27) | 34.6 (18) | 9.6 (5) | 3.8 (2) | 0.0 (0) |
| Posting the sample within 24 h of preparation | 51 | 62.7 (32) | 33.3 (17) | 3.9 (2) | 0.0 (0) | 0.0 (0) |

| I would... | Number of responses to each question (n) | Strongly agree % (n) | Agree % (n) | Neither agree nor disagree % (n) | Disagree % (n) | Strongly disagree % (n) |
|------------|------------------------------------------|---------------------|-------------|-------------------------------|----------------|---------------------|
| This service made me feel more in control of my diabetes | 55 | 27.3 (15) | 25.5 (14) | 40.0 (22) | 5.5 (3) | 1.8 (1) |
| Use this service routinely if available | 57 | 47.4 (27) | 28.1 (16) | 12.3 (7) | 10.5 (6) | 1.8 (1) |
| Prefer to use this service over attending Clinics/GP surgeries | 56 | 42.9 (24) | 25.0 (14) | 16.1 (9) | 10.7 (6) | 5.4 (3) |
| Be more likely to test for HbA1c if this service was available | 57 | 43.9 (25) | 24.6 (14) | 22.8 (13) | 7.0 (4) | 1.8 (1) |
| Be happy to collect testing pack from my local GP surgery | 55 | 32.7 (18) | 38.2 (21) | 16.4 (9) | 9.1 (5) | 3.6 (2) |
| Prefer to have the testing pack posted to my address | 55 | 50.9 (28) | 20.0 (11) | 25.5 (14) | 3.6 (2) | 0.0 (0) |
and deciding when enough blood was collected into the device. Overall participants had no difficulty posting their capillary sample on the same day of preparation or within 24 h of its preparation (Table 2). The second section of the questionnaire was used to assess user acceptance of the postal HbA1c service (Table 2). When asked if this service made them feel more in control of their diabetes management, half of the participants reported that it did, whilst a quarter of participants remained undecided. In total, 75.4% (43/57) of respondents reported that they would use this service routinely if it was available. A further 67.9% (38/56) respondents agreed that they would prefer to use this service over attending clinics or general practitioner’s surgeries for phlebotomy whilst 16.1% (9/56) reported that they would still prefer to attend appointments. In total, 68.4% (39/57) of respondents agreed that they would be more likely to test for HbA1c if this service was available.

### 3.6 Assay performance characteristics

Over the period of the study, the analytical variation (%CVA) at a mean HbA1c concentration of 36 mmol/mol (5.4%) and 67 mmol/mol (8.3%) was <2% and the assay bias ranged from 0% to 2.4%.

### 3.7 Capillary HbA1c stability

Capillary HbA1c was found to be stable up to 7 days at 4°C (Figure 4).

### 4 DISCUSSION

This was a pilot study to examine the potential use of a remote blood collection service for routine HbA1c testing. The HbA1c results from the two collection methods correlated well with each other. Regression analysis demonstrated no bias, indicating that the capillary blood collection method can be used for HbA1c measurement. The Bland–Altman difference plot indicated excellent concordance between the two methods across the wide range of HbA1c (41–131 mmol/mol [5.9%–14.1%]) concentrations assessed. One HbA1c result fell outside 5 mmol/mol (2.6%) as the difference between the venous and capillary sample was 7 mmol/mol (2.8%). The venous sample was repeated and produced the same result (66 mmol/mol [8.2%]). However, there was insufficient capillary sample to allow for a repeat analysis. Ordinarily, a repeat test result with this magnitude of difference would not be acceptable, however, for the purpose of this study, the result was included. The cause of this outlier is unknown, it may potentially be the result of an analytical or a human error.

All comparisons of HbA1c results for the six participants who had a venous sample collected a month prior to capillary sample collection were within the maximum acceptable difference of 5 mmol/mol (2.6%). These results may be considered to be as expected, given that HbA1c is a time-weighted average of blood glucose levels in the previous 30 days.15

Although many of the participants found the written instructions and YouTube video easy to follow, the largest difficulty encountered by the participants was in deciding that they had collected enough blood. This difficulty was evident in the blood volumes returned; younger participants were able to collect larger volumes of capillary blood in comparison to the more elderly participants. A further study on remote capillary collection may include an additional free-text section in the questionnaire for participants to document any specific difficulties that they may have had with sample collection. A follow-up discussion with participants particularly elderly participants may also be considered. Feedback provided by participants can provide insights into how to further develop the remote capillary collection idea.

Of note, no correlation was observed between the age of participants and the volume of capillary blood collected. However, we acknowledge that further studies with larger numbers of participants are required to verify these findings.

![Figure 4](image-url)  
**Figure 4** The stability of glycated haemoglobin (HbA1c) in capillary whole blood samples in (a) mmol/mol and (b) %.

---

**Figure 4** The stability of glycated haemoglobin (HbA1c) in capillary whole blood samples in (a) mmol/mol and (b) %.
Overall, participants had a positive experience with the MiniCollect device. Although, a quarter of participants found the device difficult to use, this difficulty was not reflected in the blood volumes returned where 11 of these participants provided sufficient blood volume for HbA1c analysis.

A small number of participants felt that they would still prefer to attend the clinic or their general practitioner (GP) for a consultation. This may be because they require other tests to be carried out in addition to HbA1c, or perhaps participants may feel that remote testing will result in a missed opportunity for discussion with their healthcare professional about their diabetes management.16 Whilst a remote blood collection service has many benefits, its value in certain cohorts of patients i.e., those with multiple co-morbidities, must be considered.

Good concordance has been reported in the literature for HbA1c measured in capillary and venous blood samples using both dried blood spot devices and collection tubes.9,16–19 Two previous studies reported that 69.2% and 70% of participants, respectively, would use a remote HbA1c service if available or recommend this service.1,16 Our study gave similar results with over three quarters of respondents (75.4% [43/57]) reporting that they would use the remote HbA1c service routinely if available.

Involvement of patients in clinical decision making has been reported to improve health outcomes and adherence to treatment/medication.20 Nwankwo et al. reported that participants (n = 8) involved in a pilot study for remote capillary sampling agreed that the remote capillary collection process resulted in better decision making and planning of care.20 Our study findings support those of Nwankwo et al., with our participants supporting a greater uptake of this remote collection approach.

There are several strengths of the study. The wide range of HbA1c concentrations obtained covered the medical decision thresholds, common glycaemic treatment targets and values indicative of high blood glucose levels. While we acknowledge that the study sample size is relatively small, the HbA1c concentration range and number of results meet the CLSI requirements to evaluate method agreement.12

A significant strength of the study is public and patient involvement; people with diabetes were involved in this study through the completion of the participant questionnaire. The information provided by participants in the questionnaire gives a valuable insight into what people with diabetes want in terms of their diabetic care.

A challenge encountered during the study was the incompatibility of the MiniCollect device with the Capillary’s 3 Tera analyser. To analyse patient samples, a specified volume of capillary blood was transferred from the MiniCollect device into a low-volume tube and put onto the instrument. These additional work-steps disrupt the normal running of the laboratory and thus if this service was used routinely, this device would not be suitable for the collection and analysis of capillary blood. In addition, the transfer of sample from one tube to another increases the potential for laboratory error to occur. If this service were to be progressed, an alternative capillary blood collection device which could be analysed directly on the laboratory instrumentation would be required. In addition, the mechanism by which results would be conveyed to people is another crucial consideration. Future work may focus on the development of a reliable communication service for remote testing.

In this study, we have shown that HbA1c results from capillary samples prepared at home and subsequently posted to the laboratory compared well and were clinically concordant with HbA1c results measured from venous samples. The collection of a finger prick blood sample at home by individuals is an inexpensive, feasible and convenient alternative to standard venous blood collection for HbA1c testing. This service provides an opportunity to support routine HbA1c monitoring, whilst mitigating the transmission of SARS-CoV-2 and adhering to public health recommendations.

**AUTHOR CONTRIBUTIONS**
Paula M. O’Shea, Wendy N. Groenendijk and Tomás P. Griffin were responsible for study concept and design. Wendy N. Groenendijk was responsible for patient recruitment, the analytical measurements and quality of analyses. Paula M. O’Shea/Wendy N. Groenendijk was responsible for data collation and Deirdre Wall statistical analysis. Wendy N. Groenendijk drafted the initial manuscript. All authors (Wendy N. Groenendijk, Tomás P. Griffin, Md N. Islam, Liam Blake, Marcia Bell, Deirdre Wall, Paula M. O’Shea) made substantial contributions to the interpretation of data, critically reviewed the manuscript for important intellectual content and approved the final version of the manuscript. Paula M. O’Shea is responsible for the integrity of the work as a whole.

**ACKNOWLEDGMENTS**
We wish to express our gratitude to all the people with diabetes, the medical, nursing and scientific staff of the Galway University Hospital and Roscommon University Hospital, Ireland, who made this research possible. We gratefully acknowledge the commitment and dedication of everyone involved.

**CONFLICT OF INTEREST**
The author(s) declare no potential conflict of interest that could be perceived as prejudicing the impartiality of the research, authorship and/or publication of this article.
ETHICAL STATEMENT

Ethical approval was granted by the Clinical Research Ethics Committee, Galway University Hospitals (Ref: C.A. 2507) and the National University of Ireland, Galway Research Ethics Committee (Ref: 17-July-05).

ORCID

Wendy N. Groenendijk © https://orcid.org/0000-0002-4113-5919
Tomás P. Griffin © https://orcid.org/0000-0001-6510-6082
Md N. Islam © https://orcid.org/0000-0002-4113-5919
Deirdre Wall © https://orcid.org/0000-0001-9392-1711
Paula M. O’Shea © https://orcid.org/0000-0001-9392-1711

REFERENCES

1. Ansari S, Abdel-Malek M, Kenkre J, et al. The use of whole blood capillary samples to measure 15 analytes for a home-collect biochemistry service during the SARS-CoV-2 pandemic: a proposed model from north West London pathology. Ann Clin Biochem. 2021;58(5):411-421.
2. Freeman VS. Glucose and hemoglobin A1c. Lab Med. 2014;45(1):c21-c24.
3. Boutayeb W, Boutayeb A, Lamili M, Ben El Mostafa S, Zitouni N. Simulation of a computed HbA1c using a weighted average glucose. SpringerPlus. 2016;5:226.
4. Higgins T. HbA1c for screening and diagnosis of diabetes mellitus. Endocrine. 2013;43(2):266-273.
5. Nathan DM, Gennuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
6. King P, Peacock I, Donnelly R. The UKprospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999;48(5):643-648.
7. Little RR, Rohlfing C, Sacks DB. The National Glycohemoglobin Standardization Program: over 20 years of improving hemoglobin A1c measurement. Clin Chem. 2019;65(7):839-848.
8. Carr MJ, Wright AK, Leelarathna L, et al. Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK. Lancet Diabetes Endocrinol. 2021;9(7):413-415.
9. Roberts AJ, Malik F, Phoker C, Dickerson JA. Adapting to telemedicine in the COVID-19 era: feasibility of dried blood spot testing for hemoglobin A1c. Diabetes Metab Syndr. 2021;15(1):433-437.
10. Greiner Bio-One. MiniCollect Capillary Blood Collection System. 2021. Accessed August 30, 2021. https://shop.gbo.com/en/row/products/preanalytics/capillary-blood-collection/minicollect-tubes/.
11. Sebia. CAPI 3 HbA1c Kit Insert. 2017.
12. CLSI. Measurement Procedure Comparison and Bias Estimation Using Patient Samples Approved Guideline - Third Edition CLSI Document EP09-A3. Clinical and Laboratory Standards Institute; 2013.
13. Sikaris K. Application of the Stockholm hierarchy to defining the quality of reference intervals and clinical decision limits. Clin Biochem Rev. 2012;33(4):141-148.
14. Weykamp C, John G, Gillery P, et al. Investigation of 2 models to set and evaluate quality targets for hba1c: biological variation and sigma-metrics. Clin Chem. 2015;61(5):752-759.
15. NGSP. HbA1c and estimated average glucose (eAG) 2010. Accessed August 30, 2021. http://www.ngsp.org/A1ceAG.asp
16. Hall JM, Fowler CF, Barrett F, Humphry RW, Van Drimmelen M, MacRury SM. HbA1c determination from HemaSpot™ blood collection devices: comparison of home prepared dried blood spots with standard venous blood analysis. Diabet Med. 2020;37(9):1463-1470.
17. Jeppsson JO, Jerntorp P, Almér LO, Persson R, Ekberg G, Sundkvist G. Capillary blood on filter paper for determination of HbA1c by ion exchange chromatography. Diabetes Care. 1996;19(2):142-145.
18. Jones TG, Warber KD, Roberts BD. Analysis of hemoglobin A1c from dried blood spot samples with the Tina-quantR II immunoturbidimetric method. J Diabetes Sci Technol. 2010;4(2):244-249.
19. Fokkema MR, Bakker AJ, de Boer F, Kooistra J, de Vries S, Wolthus A. HbA1c measurements from dried blood spots: validation and patient satisfaction. Clin Chem Lab Med. 2009;47(10):1259-1264.
20. Nwankwo L, McLaren K, Donovan J, et al. Utilisation of remote capillary blood testing in an outpatient clinic setting to improve shared decision making and patient and clinician experience: a validation and pilot study. BMJ Open Qual. 2021;10(3):e001192. doi:10.1136/bmjooq-2020-001192

How to cite this article: Groenendijk WN, Griffin TP, Islam MN, et al. Remote capillary blood collection for HbA1c measurement during the COVID-19 pandemic: A laboratory and patient perspective. Diabet Med. 2022;39:e14897. doi: 10.1111/dme.14897